An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

ABSTRACT: This purpose of this study is to evaluate nivolumab (BMS-936558) in combination with standard of care (SOC) chemotherapy with bevacizumab for the treatment of first-line metastatic colorectal cancer (mCRC).

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2264477 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR